These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 34212373)

  • 21. Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia.
    Soverini S; Branford S; Nicolini FE; Talpaz M; Deininger MW; Martinelli G; Müller MC; Radich JP; Shah NP
    Leuk Res; 2014 Jan; 38(1):10-20. PubMed ID: 24131888
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia.
    Soverini S; de Benedittis C; Mancini M; Martinelli G
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S120-8. PubMed ID: 26297264
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA.
    Sánchez R; Dorado S; Ruíz-Heredia Y; Martín-Muñoz A; Rosa-Rosa JM; Ribera J; García O; Jimenez-Ubieto A; Carreño-Tarragona G; Linares M; Rufián L; Juárez A; Carrillo J; Espino MJ; Cáceres M; Expósito S; Cuevas B; Vanegas R; Casado LF; Torrent A; Zamora L; Mercadal S; Coll R; Cervera M; Morgades M; Hernández-Rivas JÁ; Bravo P; Serí C; Anguita E; Barragán E; Sargas C; Ferrer-Marín F; Sánchez-Calero J; Sevilla J; Ruíz E; Villalón L; Del Mar Herráez M; Riaza R; Magro E; Steegman JL; Wang C; de Toledo P; García-Gutiérrez V; Ayala R; Ribera JM; Barrio S; Martínez-López J
    Sci Rep; 2022 Jul; 12(1):13057. PubMed ID: 35906470
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exome sequencing reveals DNMT3A and ASXL1 variants associate with progression of chronic myeloid leukemia after tyrosine kinase inhibitor therapy.
    Kim T; Tyndel MS; Zhang Z; Ahn J; Choi S; Szardenings M; Lipton JH; Kim HJ; Kim Dong Hwan D
    Leuk Res; 2017 Aug; 59():142-148. PubMed ID: 28667884
    [TBL] [Abstract][Full Text] [Related]  

  • 25.
    Tarantini F; Cumbo C; Zagaria A; Parciante E; Anelli L; Coccaro N; Tota G; Minervini CF; Redavid I; Rossi AR; Conserva MR; Specchia G; Musto P; Albano F
    Hematology; 2022 Dec; 27(1):842-846. PubMed ID: 35938951
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emerging kinetics of BCR-ABL1 mutations and their effect on disease outcomes in chronic myeloid leukemia patients with imatinib failure.
    Shih LY; Kuo MC; Kuo CY; Lin TH; Bai LY; Chen TY; Wang MC; Lin TL; Lan YJ; Chen CC; Yang Y; Hsiao PC; Lai CL; Chang CH; Lin TH
    Leuk Res; 2013 Jan; 37(1):43-9. PubMed ID: 23062378
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The landscape of BCR-ABL mutations in patients with Philadelphia chromosome-positive leukaemias in the era of second-generation tyrosine kinase inhibitors.
    Chien SH; Liu HM; Chen PM; Ko PS; Lin JS; Chen YJ; Lee LH; Hsiao LT; Chiou TJ; Gau JP; Yang MH; Liu CY
    Hematol Oncol; 2020 Aug; 38(3):390-398. PubMed ID: 32011024
    [TBL] [Abstract][Full Text] [Related]  

  • 28. STAT5 triggers BCR-ABL1 mutation by mediating ROS production in chronic myeloid leukaemia.
    Warsch W; Grundschober E; Berger A; Gille L; Cerny-Reiterer S; Tigan AS; Hoelbl-Kovacic A; Valent P; Moriggl R; Sexl V
    Oncotarget; 2012 Dec; 3(12):1669-87. PubMed ID: 23458731
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clonal distribution of BCR-ABL1 mutations and splice isoforms by single-molecule long-read RNA sequencing.
    Cavelier L; Ameur A; Häggqvist S; Höijer I; Cahill N; Olsson-Strömberg U; Hermanson M
    BMC Cancer; 2015 Feb; 15():45. PubMed ID: 25880391
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early BCR-ABL1 Transcript Decline after 1 Month of Tyrosine Kinase Inhibitor Therapy as an Indicator for Treatment Response in Chronic Myeloid Leukemia.
    El Missiry M; Hjorth-Hansen H; Richter J; Olson-Strömberg U; Stenke L; Porkka K; Kreutzman A; Mustjoki S
    PLoS One; 2017; 12(1):e0171041. PubMed ID: 28135325
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib.
    Castagnetti F; Gugliotta G; Breccia M; Iurlo A; Levato L; Albano F; Vigneri P; Abruzzese E; Rossi G; Rupoli S; Cavazzini F; Martino B; Orlandi E; Pregno P; Annunziata M; Usala E; Tiribelli M; Sica S; Bonifacio M; Fava C; Gherlinzoni F; Bocchia M; Soverini S; Bochicchio MT; Cavo M; Giovanni M; Saglio G; Pane F; Baccarani M; Rosti G;
    Am J Hematol; 2017 Aug; 92(8):797-805. PubMed ID: 28466557
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients.
    Soverini S; De Benedittis C; Polakova KM; Linhartova J; Castagnetti F; Gugliotta G; Papayannidis C; Mancini M; Klamova H; Salvucci M; Crugnola M; Iurlo A; Albano F; Russo D; Rosti G; Cavo M; Baccarani M; Martinelli G
    Oncotarget; 2016 Apr; 7(16):21982-90. PubMed ID: 26980736
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular monitoring of response to imatinib (Glivec) in chronic myeloid leukemia patients: experience at a tertiary care hospital in Saudi Arabia.
    Khalil SH; Abu-Amero KK; Al Mohareb F; Chaudhri NA
    Genet Test Mol Biomarkers; 2010 Feb; 14(1):67-74. PubMed ID: 19943786
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chronic myeloid leukemia patient with co-occurrence of BCR-ABL junction and JAK2 V617F mutation.
    Xu W; Chen B; Tong X
    Int J Hematol; 2014 Jan; 99(1):87-90. PubMed ID: 24293258
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular pathogenesis of Philadelphia-positive chronic myeloid leukemia - is it all BCR-ABL?
    Rumpold H; Webersinke G
    Curr Cancer Drug Targets; 2011 Jan; 11(1):3-19. PubMed ID: 21062244
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BCR/ABL-negative progenitors are enriched in the adherent fraction of CD34+ cells circulating in the blood of chronic phase chronic myeloid leukemia patients.
    Grand FH; Marley SB; Chase A; Titley I; Healy L; Spencer A; Reiter A; Goldman JM; Gordon MY
    Leukemia; 1997 Sep; 11(9):1486-92. PubMed ID: 9305602
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BCR-ABL1 positive AML or CML in blast crisis? A pediatric case report with inv(3) and t(9;22) in the initial clone.
    Behrens YL; Schienke A; Davenport C; Lentes J; Tauscher M; Steinemann D; Rasche M; Knirsch S; Joachim S; Reinhardt D; Schlegelberger B; Göhring G
    Cancer Genet; 2021 Jun; 254-255():70-74. PubMed ID: 33647814
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of a novel variant BCR-ABL1 fusion transcript in a patient with chronic myeloid leukemia: Implications for molecular monitoring.
    Crampe M; Haslam K; Kelly J; Conneally E; Langabeer SE
    Hematol Oncol Stem Cell Ther; 2017 Jun; 10(2):85-88. PubMed ID: 27013275
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genomic amplification of BCR-ABL1 fusion gene and its impact on the disease progression mechanism in patients with chronic myelogenous leukemia.
    Chandran RK; Geetha N; Sakthivel KM; Aswathy CG; Gopinath P; Raj TVA; Priya G; Nair JKKM; Sreedharan H
    Gene; 2019 Feb; 686():85-91. PubMed ID: 30399426
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical characteristics and prognostic significance of chronic myeloid leukemia with rare BCR-ABL1 transcripts.
    Xue M; Wang Q; Huo L; Wen L; Yang X; Wu Q; Pan J; Cen J; Ruan C; Wu D; Chen S
    Leuk Lymphoma; 2019 Dec; 60(12):3051-3057. PubMed ID: 31258010
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.